u/zaid_balogun

switching from sema is not a dose conversion, there is no clean equivalence

2.5 is the starter dose and it is not meant to be the dose that works

Constipation is mostly reduced intake plus reduced fluid, not a direct effect. That is why the boring fibre and water answer keeps working.

regional stock changes everything about transit

Discharge from a specialist service at goal is a normal end point of that pathway.

This is why national advice does not work here. It is commissioned locally and it varies.

GP said no in the spring, specialist said yes eighteen months later. Same person, same numbers.

What did the referral letter actually say?

Correction: that is net peptide content, not purity. Different number, different meaning, and the document says so if you read the row label.

Pushback: you changed the dose, the meal timing and the training in the same fortnight, so the attribution is guesswork.

Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.

LC-MS gives you identity; UV purity gives you a relative quantity. A document with the first and not the second, or the reverse, is answering half the question.

chromatogram or it did not happen

How long after a step up did this start?

2.5mg is a four-week starting dose, not a maintenance dose. Worth being precise since people search these threads.

Small fix — shipped from the regional warehouse, not from origin, which is why the number looks unusual.

Started keeping a folder of every certificate I have been sent. The ones that itemise impurities are a small group and they are mostly the same suppliers.

Pen or vial? The step sizes available differ and it changes this answer.

Net peptide content is the fraction of the powder that is actually peptide once counterion, water and residual solvent are accounted for. A 99% pure acetate salt can still be about 85% peptide by mass.

Agreed — it is an amylin analogue and importing intuitions from the incretin boards produces confident nonsense.

Adding the standing caveat — nothing here is approved standalone and research material is not for human use.

This. The monthly pricing tracker is the most useful thing on this board and it works because nobody is allowed to link anything.

That reads like advice, and none of us can give it. Describe what you did, not what somebody else should do.

the appetite effect is blunter than sema, in a good way, most weeks

The effect on gastric emptying is most pronounced early and attenuates with continued dosing, which is the mechanism behind the "it settles at a stable dose" pattern the whole board reports.

I would not read a supply notice as a shortage in your pharmacy tomorrow. They are not the same thing.

2.5mg is a four-week starting dose, not a maintenance dose. Worth being precise since people search these threads.

That only works if the fill weight is exactly the label weight, and it usually is not exactly anything.

week 4 is early to draw any conclusion at all

Shook the first vial because nobody told me not to. It was fine, but I have swirled every one since.

batch number, date of analysis, method, individual impurities — that is the minimum set

SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category error.

reconstituting at a round concentration makes every later dose easy

Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.

axis labels included, always

Agreed, and the practical version is: ask for the itemised table. If it exists, you get it.

Water content 3.8%, acetate 6.2%, purity 99%, net peptide about 90% of label weight. All four numbers honest, and I had to read it twice.

Regional stock replaces an international lane with a domestic one. That is a structural change to the distribution, not a marginal improvement, and it is why the warehouse question matters more than the carrier question.

a certificate with no method line is decorative

That symptom is not the one being described upthread.

Agreed, with the caveat that "usually settles" is not "always settles" and the exceptions should still get asked about properly.

This. A quoted lead time that holds is worth more than a fast one that does not.

Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.